![Robert Dean Prentiss](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert Dean Prentiss
Keine laufenden Positionen mehr
Karriereverlauf von Robert Dean Prentiss
Ehemalige bekannte Positionen von Robert Dean Prentiss
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IDENIX PHARMACEUTICALS INC | Comptroller/Controller/Auditor | 01.08.2011 | 01.09.2014 |
Finanzdirektor/CFO | 01.08.2011 | 01.09.2014 | |
TRANSLATE BIO, INC. | Comptroller/Controller/Auditor | 01.01.2015 | - |
Finanzdirektor/CFO | 01.01.2015 | 01.03.2017 | |
Treasurer | - | - | |
Biopure Corp.
![]() Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | - | - |
Ausbildung von Robert Dean Prentiss
Salem State University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Comptroller/Controller/Auditor | 3 |
Director of Finance/CFO | 2 |
Treasurer | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Biopure Corp.
![]() Biopure Corp. Pharmaceuticals: MajorHealth Technology Biopure Corp. developed, manufactured and marketed oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. The company used patented and proprietary technology to develop and manufacture two products: Hemopure for human use, and Oxyglobin for veterinary use. It has developed Hemopure for the treatment of patients with cardiovascular ischemia. Oxyglobin, its veterinary product treated anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission. Biopure was founded in 1984 and was headquartered in Cambridge, MA. | Health Technology |
Translate Bio, Inc.
![]() Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
Idenix Pharmaceuticals LLC
![]() Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Robert Dean Prentiss
- Erfahrung